Blood Collection Protocol for the Analysis of Exosomes in Patients with Breast Cancer

Cancer
Ritesh Parajuli
Blood Collection Protocol for the Analysis of Exosomes in Patients with Breast Cancer
Breast

Study Description

Scientists and clinicians at this institution are working together to discover new ways to monitor cancer

and find tests that could detect recurrence early on. The purpose of this research study is to determine

a group of particles in the blood called exosomes that may be associated with response to treatment

or could predict recurrence and side effects.

Eligibility

Please note this may not be a complete list of eligibility criteria. We have included a few examples of

study criteria to help you better understand how your eligibility in the study will be determined; your study

team will go through the study eligibility criteria with you to verify if you qualify for participation in this

study.

You can participate in this study if you:

  • Are female
  • Over the age of 18
  • Ability to understand and the willingness to sign a written informed consent document
  • Consent to be in the study, signed and dated an approved consent form, which conforms to federal and institutional guidelines.
  • For cancer patients, you must have either Stage I, Stage II, Stage III or Stage IV Breast cancer
  • For cancer patients, you must have either hormone Receptor +, Her-2 receptor positive, triple

positive or triple negative breast cancer

You cannot participate in this study if you

  • Are physically or mentally incapable to give verbal or written consent
  • For cancer patients: have other active cancers expect for cured skin and in situ cervical cancer
  • For non-cancer participants: history of cancer diagnosis or prior exposure to chemotherapy

agents

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.